Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors.
Identifieur interne : 000D22 ( PubMed/Curation ); précédent : 000D21; suivant : 000D23Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors.
Auteurs : Bao-Long Chen [République populaire de Chine] ; Ya-Jing Wang [République populaire de Chine] ; Hong Guo [République populaire de Chine] ; Guang-Yao Zeng [République populaire de Chine]Source :
- European journal of medicinal chemistry [ 1768-3254 ] ; 2016.
Descripteurs français
- KwdFr :
- Acides caféiques (), Acides caféiques (pharmacologie), Antienzymes (), Antienzymes (pharmacologie), Antiviraux (), Antiviraux (pharmacologie), Conception de médicament, Glucosides (), Glucosides (pharmacologie), Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Humains, Modèles moléculaires, Relation structure-activité, Sialidase (antagonistes et inhibiteurs), Sialidase (métabolisme), Sous-type H1N1 du virus de la grippe A (), Sous-type H1N1 du virus de la grippe A (enzymologie), Virus de la grippe A (), Virus de la grippe A (enzymologie).
- MESH :
- antagonistes et inhibiteurs : Sialidase.
- enzymologie : Sous-type H1N1 du virus de la grippe A, Virus de la grippe A.
- métabolisme : Sialidase.
- pharmacologie : Acides caféiques, Antienzymes, Antiviraux, Glucosides.
- traitement médicamenteux : Grippe humaine.
- virologie : Grippe humaine.
- Acides caféiques, Antienzymes, Antiviraux, Conception de médicament, Glucosides, Humains, Modèles moléculaires, Relation structure-activité, Sous-type H1N1 du virus de la grippe A, Virus de la grippe A.
English descriptors
- KwdEn :
- Antiviral Agents (chemistry), Antiviral Agents (pharmacology), Caffeic Acids (chemistry), Caffeic Acids (pharmacology), Drug Design, Enzyme Inhibitors (chemistry), Enzyme Inhibitors (pharmacology), Glucosides (chemistry), Glucosides (pharmacology), Humans, Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H1N1 Subtype (enzymology), Influenza A virus (drug effects), Influenza A virus (enzymology), Influenza, Human (drug therapy), Influenza, Human (virology), Models, Molecular, Neuraminidase (antagonists & inhibitors), Neuraminidase (metabolism), Structure-Activity Relationship.
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , chemistry : Antiviral Agents, Caffeic Acids, Enzyme Inhibitors, Glucosides.
- chemical , metabolism : Neuraminidase.
- chemical , pharmacology : Antiviral Agents, Caffeic Acids, Enzyme Inhibitors, Glucosides.
- drug effects : Influenza A Virus, H1N1 Subtype, Influenza A virus.
- drug therapy : Influenza, Human.
- enzymology : Influenza A Virus, H1N1 Subtype, Influenza A virus.
- virology : Influenza, Human.
- Drug Design, Humans, Models, Molecular, Structure-Activity Relationship.
Abstract
Natural products, especially derived from TCMH, have been found to exert antiviral effects against influenza virus. Crenatoside, a phenylethanoid glycoside from Pogostemon cablin Benth, which has been shown as a novel effective NA inhibitor previously, is considered as the leading compound for our further SARs studies. This work presented design, synthesis of novel crenatoside analogues from readily available d-Glucose and l-rhamnose in a convergent manner. Furthermore, their biological activities and SARs were also investigated. Especially, compound 2 h showed impressive IC50 = 27.77 μg/mL against NAs, which is 3 folds more potent than the leading compound crenatoside (IC50 = 89.81 μg/mL). These results would promise their therapeutic potential for influenza disease.
DOI: 10.1016/j.ejmech.2015.12.031
PubMed: 26774928
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D22
Links to Exploration step
pubmed:26774928Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors.</title><author><name sortKey="Chen, Bao Long" sort="Chen, Bao Long" uniqKey="Chen B" first="Bao-Long" last="Chen">Bao-Long Chen</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Ya Jing" sort="Wang, Ya Jing" uniqKey="Wang Y" first="Ya-Jing" last="Wang">Ya-Jing Wang</name><affiliation wicri:level="1"><nlm:affiliation>Hunan University of Chinese Medicine, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Hunan University of Chinese Medicine</wicri:regionArea></affiliation></author><author><name sortKey="Guo, Hong" sort="Guo, Hong" uniqKey="Guo H" first="Hong" last="Guo">Hong Guo</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013</wicri:regionArea></affiliation></author><author><name sortKey="Zeng, Guang Yao" sort="Zeng, Guang Yao" uniqKey="Zeng G" first="Guang-Yao" last="Zeng">Guang-Yao Zeng</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013, PR China. Electronic address: zenggy2013@csu.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26774928</idno><idno type="pmid">26774928</idno><idno type="doi">10.1016/j.ejmech.2015.12.031</idno><idno type="wicri:Area/PubMed/Corpus">000D22</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D22</idno><idno type="wicri:Area/PubMed/Curation">000D22</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D22</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors.</title><author><name sortKey="Chen, Bao Long" sort="Chen, Bao Long" uniqKey="Chen B" first="Bao-Long" last="Chen">Bao-Long Chen</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Ya Jing" sort="Wang, Ya Jing" uniqKey="Wang Y" first="Ya-Jing" last="Wang">Ya-Jing Wang</name><affiliation wicri:level="1"><nlm:affiliation>Hunan University of Chinese Medicine, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Hunan University of Chinese Medicine</wicri:regionArea></affiliation></author><author><name sortKey="Guo, Hong" sort="Guo, Hong" uniqKey="Guo H" first="Hong" last="Guo">Hong Guo</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013</wicri:regionArea></affiliation></author><author><name sortKey="Zeng, Guang Yao" sort="Zeng, Guang Yao" uniqKey="Zeng G" first="Guang-Yao" last="Zeng">Guang-Yao Zeng</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013, PR China. Electronic address: zenggy2013@csu.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013</wicri:regionArea></affiliation></author></analytic><series><title level="j">European journal of medicinal chemistry</title><idno type="eISSN">1768-3254</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (chemistry)</term><term>Antiviral Agents (pharmacology)</term><term>Caffeic Acids (chemistry)</term><term>Caffeic Acids (pharmacology)</term><term>Drug Design</term><term>Enzyme Inhibitors (chemistry)</term><term>Enzyme Inhibitors (pharmacology)</term><term>Glucosides (chemistry)</term><term>Glucosides (pharmacology)</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (drug effects)</term><term>Influenza A Virus, H1N1 Subtype (enzymology)</term><term>Influenza A virus (drug effects)</term><term>Influenza A virus (enzymology)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (virology)</term><term>Models, Molecular</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Neuraminidase (metabolism)</term><term>Structure-Activity Relationship</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acides caféiques ()</term><term>Acides caféiques (pharmacologie)</term><term>Antienzymes ()</term><term>Antienzymes (pharmacologie)</term><term>Antiviraux ()</term><term>Antiviraux (pharmacologie)</term><term>Conception de médicament</term><term>Glucosides ()</term><term>Glucosides (pharmacologie)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Modèles moléculaires</term><term>Relation structure-activité</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Sialidase (métabolisme)</term><term>Sous-type H1N1 du virus de la grippe A ()</term><term>Sous-type H1N1 du virus de la grippe A (enzymologie)</term><term>Virus de la grippe A ()</term><term>Virus de la grippe A (enzymologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term><term>Caffeic Acids</term><term>Enzyme Inhibitors</term><term>Glucosides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Caffeic Acids</term><term>Enzyme Inhibitors</term><term>Glucosides</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Acides caféiques</term><term>Antienzymes</term><term>Antiviraux</term><term>Glucosides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Design</term><term>Humans</term><term>Models, Molecular</term><term>Structure-Activity Relationship</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Acides caféiques</term><term>Antienzymes</term><term>Antiviraux</term><term>Conception de médicament</term><term>Glucosides</term><term>Humains</term><term>Modèles moléculaires</term><term>Relation structure-activité</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Virus de la grippe A</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Natural products, especially derived from TCMH, have been found to exert antiviral effects against influenza virus. Crenatoside, a phenylethanoid glycoside from Pogostemon cablin Benth, which has been shown as a novel effective NA inhibitor previously, is considered as the leading compound for our further SARs studies. This work presented design, synthesis of novel crenatoside analogues from readily available d-Glucose and l-rhamnose in a convergent manner. Furthermore, their biological activities and SARs were also investigated. Especially, compound 2 h showed impressive IC50 = 27.77 μg/mL against NAs, which is 3 folds more potent than the leading compound crenatoside (IC50 = 89.81 μg/mL). These results would promise their therapeutic potential for influenza disease. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26774928</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1768-3254</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><PubDate><Year>2016</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>European journal of medicinal chemistry</Title><ISOAbbreviation>Eur J Med Chem</ISOAbbreviation></Journal><ArticleTitle>Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors.</ArticleTitle><Pagination><MedlinePgn>199-205</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmech.2015.12.031</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0223-5234(15)30417-7</ELocationID><Abstract><AbstractText>Natural products, especially derived from TCMH, have been found to exert antiviral effects against influenza virus. Crenatoside, a phenylethanoid glycoside from Pogostemon cablin Benth, which has been shown as a novel effective NA inhibitor previously, is considered as the leading compound for our further SARs studies. This work presented design, synthesis of novel crenatoside analogues from readily available d-Glucose and l-rhamnose in a convergent manner. Furthermore, their biological activities and SARs were also investigated. Especially, compound 2 h showed impressive IC50 = 27.77 μg/mL against NAs, which is 3 folds more potent than the leading compound crenatoside (IC50 = 89.81 μg/mL). These results would promise their therapeutic potential for influenza disease. </AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Bao-Long</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ya-Jing</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Hunan University of Chinese Medicine, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Guang-Yao</ForeName><Initials>GY</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Central South University, 172 Tongzipo Road, Yuelu District, Changsha 410013, PR China. Electronic address: zenggy2013@csu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Eur J Med Chem</MedlineTA><NlmUniqueID>0420510</NlmUniqueID><ISSNLinking>0223-5234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002109">Caffeic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005960">Glucosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>145985-09-7</RegistryNumber><NameOfSubstance UI="C083069">crenatoside</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002109" MajorTopicYN="N">Caffeic Acids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005960" MajorTopicYN="N">Glucosides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Crenatoside derivatives</Keyword><Keyword MajorTopicYN="N">Design</Keyword><Keyword MajorTopicYN="N">Influenza virus</Keyword><Keyword MajorTopicYN="N">Neuraminidases inhibitors</Keyword><Keyword MajorTopicYN="N">Synthesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>07</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26774928</ArticleId><ArticleId IdType="pii">S0223-5234(15)30417-7</ArticleId><ArticleId IdType="doi">10.1016/j.ejmech.2015.12.031</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D22 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000D22 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26774928
|texte= Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26774928" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |